Adverse drug reactions associated with COVID-19 management.

ACTIV-3/TICO Study Group*, Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM, Rogers R, Shehadeh F, Kaczynski M, Mylona EK, Syrigos KN, Rapti V, Lye DC, Hui DS, Leither L, Knowlton KU, Jain MK, Marines-Price R, Osuji A, Overcash JS, Kalomenidis I, Barmparessou Z, Waters M, Zepeda K, Chen P, Torbati S, Kiweewa F, Sebudde N, Almasri E, Hughes A, Bhagani SR, Rodger A, Sandkovsky U, Gottlieb RL, Nnakelu E, Trautner B, Menon V, Lutaakome J, Matthay M, Robinson P, Protopapas K, Koulouris N, Kimuli I, Baduashvili A, Braun DL, Günthard HF, Ramachandruni S, Kidega R, Kim K, Hatlen TJ, Phillips AN, Murray DD, Jensen TO, Padilla ML, Accardi EX, Shaw-Saliba K, Dewar RL, Teitelbaum M, Natarajan V, Laverdure S, Highbarger HC, Rehman MT, Vogel S, Vallée D, Crew P, Atri N, Schechner AJ, Pett S, Hudson F, Badrock J, Touloumi G, Brown SM, Self WH, North CM, Ginde AA, Chang CC, Kelleher A, Nagy-Agren S, Vasudeva S, Looney D, Nguyen HH, Sánchez A, Weintrob AC, Grund B, Sharma S, Reilly CS, Paredes R, Bednarska A, Gerry NP, Babiker AG, Davey VJ, Gelijns AC, Higgs ES, Kan V, Matthews G, Thompson BT, Legenne P, Chandra R, Lane HC, Neaton JD, Lundgren JD, Barkauskas C, Mylonakis E, Poulakou G, Young BE, Vock DM, Siegel L, Engen N, Grandits G, Mosaly NR, Vekstein AM, Rogers R, Shehadeh F, Kaczynski M, Mylona EK, Syrigos KN, Rapti V, Lye DC, Hui DS, Leither L, Knowlton KU, Jain MK, Marines-Price R, Osuji A, Overcash JS, Kalomenidis I, Barmparessou Z, Waters M, Zepeda K, Chen P, Torbati S, Kiweewa F, Sebudde N, Almasri E, Hughes A, Bhagani SR, Rodger A, Sandkovsky U, Gottlieb RL, Nnakelu E, Trautner B, Menon V, Lutaakome J, Matthay M, Robinson P, Protopapas K, Koulouris N, Kimuli I, Baduashvili A, Braun DL, Günthard HF, Ramachandruni S, Kidega R, Kim K, Hatlen TJ, Phillips AN, Murray DD, Jensen TO, Padilla ML, Accardi EX, Shaw-Saliba K, Dewar RL, Teitelbaum M, Natarajan V, Laverdure S, Highbarger HC, Rehman MT, Vogel S, Vallée D, Crew P, Atri N, Schechner AJ, Pett S, Hudson F, Badrock J, Touloumi G, Brown SM, Self WH, North CM, Ginde AA, Chang CC, Kelleher A, Nagy-Agren S, Vasudeva S, Looney D, Nguyen HH, Sánchez A, Weintrob AC, Grund B, Sharma S, Reilly CS, Paredes R, Bednarska A, Gerry NP, Babiker AG, Davey VJ, Gelijns AC, Higgs ES, Kan V, Matthews G, Thompson BT, Legenne P, Chandra R, Lane HC, Neaton JD, Lundgren JD, Sahner D, Tierney J, Herpin BR, Smolskis MC, McKay LA, Cahill K, Sardana R, Raim SS, Hensely L, Lorenzo J, Mock R, Zuckerman J, Miller M, Chung L, Kang N, Adam SJ, Read S, Draghia-Akli R, Carlsen A, Carter A, Denning E, DuChene A, Eckroth K, Frase A, Gandits G, Harrison M, Kaiser P, Koopmeiners J, Meger S, Murray T, Quan K, Quan SF, Thompson G, Walski J, Wentworth D, Moskowitz AJ, Bagiella E, Moquete E, O’Sullivan K, Marks ME, Kinzel E, Burris S, Bedoya G, Gupta L, Overbey JR, Padillia ML, Santos M, Gillinov MA, Miller MA, Taddei-Peters WC, Fenton K, Mack M, Berhe M, Haley C, Dishner E, Bettacchi C, Golden K, Duhaime E, Ryan M, Burris S, Tallmadge C, Estrada L, Jones F, Villa S, Wang S, Robert R, Coleman T, Clariday L, Baker R, Hurutado-Rodriguez M, Iram N, Fresnedo M, Davis A, Leonard K, Ramierez N, Thammavong J, Duque K, Turner E, Fisher T, Robinson D, Ransom D, Maldonado N, Lusk E, Killian A, Palacious A, Solis E, Jerrow J, Watts M, Whitacre H, Cothran E, Smith PK, Ko ER, Dreyer GR, Stafford N, Brooks M, Der T, Witte M, Gamarallage R, Franzone J, Ivey N, Lumsden RH, Mourad A, Holland TL, Motta M, Lane K, McGowan LM, Stout J, Aloor H, Bragg KM, Toledo B, McLendon-Arvik B, Bussadori B, Hollister BA, Griffin M, Giangiacomo DM, Rodriguez V, Parrino PE, Spindel S, Bansal A, Baumgarten K, Hand J, Vonderhaar D, Nossaman B, Laudun S, Ames D, Broussard S, Hernandez N, Isaac G, Dinh H, Zheng Y, Tran S, McDaniel H, Crovetto N, Perin E, Costello B, Manian P, Sohail MR, Postalian A, Hinsu P, Watson C, Chen J, Fink M, Sturgis L, Kim W, Mahon K, Parenti J, Kappenman C, Knight A, Sturek JM, Barros A, Enfield KB, Kadl A, Green CJ, Simon RM, Fox A, Thornton K, Adams A, Traverse JH, Rhame F, Huelster J, Kethireddy R, Salamanca J, Majeski C, Skelton P, Zarambo M, Sarafolean A, Oldmixon C, Ringwood N, Muzikansky A, Morse R, Brower RG, Reineck LA, Aggarwal NR, Bienstock K, Steingrub JH, Hou PK, Steingrub JS, Tidswell MA, Kozikowski L-A, Kardos C, DeSouza L, Romain S, Talmor D, Shapiro N, Andromidas K, Banner-Goodspeed V, Bolstad M, Boyle KL, Cabrera P, deVilla A, Ellis JC, Grafals A, Hayes S, Higgins C, Kurt L, Kurtzman N, Redman K, Rosseto E, Scaffidi D, Shapiro N, Talmor D, Filbin MR, Hibbert KA, Parry B, Margolin J, Hillis B, Hamer R, Jones AE, Galbraith J, Nandi U, Hendey G, Matthay MA, Kangelaris K, Ashktorab K, Gropper R, Agrawal A, Almasri E, Fayed M, Hubel KA, Garcia RL, Lim GW, Chang SY, Hendey G, Lin MY, Vargas J, Sihota H, Beutler R, Rogers AJ, Wilson JG, Vojnik R, Perez C, McDowell JH, Albertson T, Hardy E, Harper R, Moss MA, Ginde AA, Chauhan L, Douin DJ, Martinez F, Finck LL, Bastman J, Hyzy RC, Park PK, Hyzy RC, Park PK, Nelson K, McSparron JI, Co IN, Wang BR, Jimenez J, Sullins B, Olbrich N, Gong MN, Richardson LD, Gong MN, Nair R, Lopez B, Amosu O, Tzehaie H, Nkemdirim W, Boujid S, Mosier JM, Hypes C, Campbell ES, Bixby B, Gilson B, Lopez A, Hite RD, Terndrup TE, Wiedemann HP, Hudock K, Tanzeem H, More H, Martinkovic J, Sellers S, Houston J, Burns M, Hough CL, Robinson BH, Hough CL, Khan A, Krol OF, Mills E, Kinjal M, Briceno G, Reddy R, Hubel K, Parimon T, Caudill A, Mattison B, Jackman SE, Chen P-E, Bayoumi E, Ojukwu C, Fine D, Weissberg G, Isip K, Choi-Kuaea Y, Mehdikhani S, Dar TB, Augustin NBF, Tran D, Dukov JE, O’Mahony DS, Wilson DM, Wallick JA, Duven AM, Fletcher DD, Files DC, Miller C, Gibbs KW, Flores LS, LaRose ME, Landreth LD, Palacios DR, Parks L, Hicks M, Goodwin AJ, Kilb EF, Lematty CT, Patti K, Bledsoe J, Brown S, Lanspa M, Pelton I, Armbruster BP, Montgomery Q, Kumar N, Fergus M, Imel K, Palmer G, Webb B, Klippel C, Jensen H, Duckworth S, Gray A, Burke Tyler, Knox D, Lumpkin J, Aston VT, Rice TW, Self WH, Rice TW, Casey JD, Johnson J, Hays M, Kasubhai M, Pillai A, Daniel J, Sittler D, Kanna B, Jilani N, Amaro F, Santana J, Lyakovestsky A, Madhoun I, Desroches LM, Amadon N, Bahr A, Ezzat I, Guerrero M, Padilla J, Fullmer J, Singh I, Ali Shah SH, Narang R, Mock P, Shadle M, Hernandez B, Welch K, Payne A, Ertl G, Canario D, Barrientos I, Goss D, DeVries M, Folowosele I, Garner D, Gomez M, Price J, Bansal E, Wong J, Faulhaber J, Fazili T, Yeary B, Ndolo R, Bryant C, Smigeil B, Najjar R, Jones P, Nguyen J, Chin C, Taha H, Najm S, Smith C, Moore J, Nassar T, Gallinger N, Christian A, Mauer D, Phipps A, Coslet J, Landazuri R, Pineda J, Uribe N, Garcia JR, Barbabosa C, Sandler K, Marquez A, Chu H, Lee K, Quillin K, Garcia A, Lew P, Tran Q-L, Benitez G, Mishra B, Felix LO, Vafea MT, Atalla E, Davies R, Hedili S, Monkeberg MA, Tabler S, Mylonakis E, Rogers R, Shehadeh F, Mylona EK, Kaczynski M, Tran Q-L, Benitez G, Mishra B, Felix LO, Vafea MT, Atalla E, Davies R, Hedili S, Harrington B, Popielski L, Kambo A, Viens K, Turner M, Vjecha MJ, Osuji A, Agbor BTA, Petersen T, Kamel D, Hansen L, Garcia A, Cha C, Mozaffari A, Hernandez R, Jain MK, Agbor BTA, Petersen T, Kamel D, Hansen L, Garcia Angie, Kim M, DellaValle N, Gonzales S, Somboonwit C, Oxner A, Guerra L, Tran T, Pinto A, Anderson B, Zepeda-Gutierrez A, Martin D, Temblador C, Cuenca A, Guerrero M, Daar E, Correa R, Hartnell G, Wortmann G, Doshi S, Moriarty T, Gonzales M, Garman K, Baker JV, Frosch A, Goldsmith R, Jibrell H, Lo M, Klaphake J, Mackedanz S, Ngo L, Garcia-Myers K, Kunisaki KM, Hassler M, Walquist M, Augenbraun M, Dehovitz J, Abassi M, Leuck A-M, Rao V, Biswas K, Harrington C, Garcia A, Bremer T, Burke Tara, Koker B, Davis-Karim A, Pittman D, Vasudeva SS, Pandit L, Hines-Munson C, Van J, Dillon L, Wang Y, Ochalek T, Caldwell E, Humerickhouse E, Boone D, McGraw W, Mehta SR, Johns ST, StJohn M, Raceles J, Sear E, Funk S, Cesarini R, Fang M, Nicalo K, Drake W, Jones B, Holtman T, Maniar A, Johnson EA, Nguyen L, Tran MT, Barrett TW, Johnston T, Huggins JT, Beiko TY, Hughes HY, McManigle WC, Tanner NT, Washburn RG, Ardelt M, Tuohy PA, Mixson JL, Hinton CG, Thornley N, Allen H, Elam S, Boatman B, Baber BJ, Ryant R, Roller B, Nguyen C, Mikail AM, Hansen M, Lichtenberger P, Baracco G, Ramos C, Bjork L, Sueiro M, Tien P, Freasier H, Buck T, Nekach H, Holodniy M, Chary A, Lu K, Peters T, Lopez J, Tan SY, Lee RH, Asghar A, Isip TKK, Le K, Nguyen T, Wong S, Raben D, Aagaard B, Nielsen CB, Krapp K, Nykjær BR, Olsson C, Kanne KL, Grevsen AL, Joensen ZM, Bruun T, Bojesen A, Woldbye F, Normand NE, Benfield T, Clausen CL, Hovmand N, Israelsen SB, Iversen K, Leding C, Pedersen KB, Thorlacius-Ussing L, Tinggaard M, Tingsgard S, Jensen J-US, Overgaard R, Rastoder E, Heerfordt C, Hedsund C, Ronn CP, Kamstrup PT, Hogsberg DS, Bergsoe C, Ostergaard L, Staerke NB, Yehdego Y, Sondergaard A, Johansen IS, Holden IK, Lindvig SO, Helleberg M, Gerstoft J, Kirk O, Bruun T, Jensen TO, Madsen BL, Pedersen TI, Harboe ZB, Roge BT, Hansen TM, Glesner MK, Lofberg SV, Nielsen AD, Nielsen H, Thisted RK, Petersen KT, Juhl MR, Podlekareva D, Johnsen S, Wiese L, Knudsen LS, Expósito M, Badillo J, Martínez A, Abad E, Chamorro A, Mateu L, España S, Lucero MC, Santos JR, Lladós G, Lopez C, Carabias L, Fernández-Cruz E, Di Natale M, Padure S, Gomez J, Ausin C, Cervilla E, Balastegui H, Sainz CR, Lopez P, Escobar M, Balerdi L, Legarda A, Roldan M, Letona L, Muñoz J, Arribas JR, Sánchez RM, Díaz-Pollán B, Stewart SM, Garcia I, Borobia A, Estrada V, Cabello N, Nuñez-Orantos MJ, Sagastagoitia I, Homen JR, Orviz E, Montalvá AS, Espinosa-Pereiro J, Bosch-Nicolau P, Salvador F, Morales-Rull JL, Pena AMM, Acosta C, Solé-Felip C, West E, M’Rabeth-Bensalah K, Eichinger ML, Grüttner-Durmaz M, Grube C, Zink V, Goes J, Tsertsvadze T, Abutidze A, Chkhartishvili N, Metchurtchlishvili R, Endeladze M, Paciorek M, Bursa D, Krogulec D, Pulik P, Ignatowska A, Fishchuk R, Kobrynska O, Levandovska K, Kirieieva I, Kuziuk M, Polizzotto M, Carey C, Dharan NJ, Hough S, Virachit S, Davidson S, Bice DJ, Ognenovska K, Cabrera G, Flynn R, Chia PY, Lee TH, Lin RJ, Ong SWX, Puah SH, Yeo TW, Ongko J, Yeo HP, Kwaghe V, Zaiyad H, Idoko G, Uche B, Selvamuthu P, Kumarasamy N, Beulah FE, Govindarajan N, Mariyappan K, Losso MH, Abela C, Moretto R, Belloc CG, Ludueña J, Amar J, Losso MH, Toibaro J, Macias LM, Fernandez L, Frare PS, Chaio SR, Pachioli V, Timpano SM, Sanchez MDL, Sierra MDP, Stanek V, Belloso W, Cilenti FL, Valentini RN, Stryjewski ME, Locatelli N, Riera MCS, Salgado C, Baeck IM, Di Castelnuovo V, Zarza SM, Parmar MKB, Goodman AL, Gregory A, Goodall K, Harris N, Wyncoll J, Luntiel A, Patterson C, Morales J, Witele E, Preston AM, Nandani A, Price DA, Nell J, Patel B, Hays C, Jones G, Davidson J, Pantazis N, Gioukari V, Souliou T, Antoniadou A, Kavatha D, Grigoropoulou S, Tziolos RN, Oikonomopoulo C, Moschopoulos C, Tzimopoulos K, Koromilias A, Argyraki K, Lourida P, Bakakos P, Vlachakos V, Balis E, Zakynthinos S, Sigala I, Gianniou N, Dima E, Magkouta S, Synolaki E, Konstanta S, Vlachou M, Stathopoulou P, Panagopoulos P, Petrakis V, Papazoglou D, Tompaidou E, Isaakidou E, Leontis K, Nitsotolis T, Athanasiou K, Myrodia MD, Kyriakoulis K, Trontzas I, Arfara-Melanini M, Kolonia V, Kityo C, Mugerwa H, Lukaakome J, Nsereko C, Lubega G, Kibirige M, Nakahima W, Wangi D, Aguti E, Generous L, Massa R, Nalaki M, Magala F, Nabaggala PK, Kityo C, Mugerwa H, Faith OD, Florence A, Emmanuel O, Beacham MP, Geoffrey A, Nakiboneka D, Apiyo P, Kiweewa F, Kirenga B, Kimuli I, Atukunda A, Muttamba W, Remmy K, Segawa I, Pheona N, Kigere D, Mbabazi QL, Boersalino L, Nyakoolo G, Kiweewa F, Fred A, Alupo A, Ebong D, Monday E, Nalubwama RN, Kainja M, Ambrose M, Kwehayo V, Nalubega MG, Ongoli A, Obbo S, Alaba J, Magombe G, Tino H, Obonya E, Lutaakome J, Kitonsa J, Onyango M, Naboth T, Naluyinda H, Nanyunja R, Irene M, Jane B, Wimfred K, Leonar S, Deus T, Babra N, Taire P, Lutaakone J, Nabankema E, Ogavu J, Mugerwa O, Okoth I, Mwebaze R, Mugabi T, Makhoba A, Arikiriza P, Theresa N, Nakayima H, Frank K, Ramgi P, Pereira K, Osinusi A, Cao H, Stumpp M, Goncalves S, Ramanathan K, Baseler B, Holley HP, Jankelevich S, Adams A, Becker N, Dolney S, Hissey D, Simpson S, Kim MH, Beeler J, Harmon L, Asomah M, Jato Y, Stottlemyer A, Tang O, Vanderpuye S, Yeon L, Buehn M, Eccard-Koons V, Frary S, MacDonald L, Cash J, Hoopengardner L, Linton J, Schaffhauser M, Nelson M, Spinelli-Nadzam M, Proffitt C, Lee C, Engel T, Fontaine L, Osborne CK, Hohn M, Galcik M, Thompson D, Chang W, Sherman BT, Rupert AW, Baseler M, Lallemand P, Imamichi T, Paudel S, Cook K, Haupt K, Highbarger J, Hazen A, Badralmaa Y, Smith K, Patel B, Kubernac R, Hoover ML, Brown C, DuChateau N, Ellis S, Flosi A, Fox L, Johnson L, Nelson R, Stojanovic J, Treagus A, Wenner C, Williams R (2022) Efficacy and safety of ensovibep for adults hospitalized with COVID-19: a randomized controlled trial. Ann Intern Med 175:1266–1274. https://doi.org/10.7326/M22-1503

doi: 10.7326/M22-1503

Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR (2018) Coronavirus susceptibility to the antiviral is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9:e00221-18. https://doi.org/10.1128/mBio.00221-18

doi: 10.1128/mBio.00221-18 pubmed: 29511076 pmcid: 5844999

Agrawal U, Raju R, Udwadia ZF (2020) Favipiravir: a new and emerging antiviral option in COVID-19. Med J Armed Forces India 76:370–376. https://doi.org/10.1016/j.mjafi.2020.08.004

doi: 10.1016/j.mjafi.2020.08.004 pubmed: 32895599 pmcid: 7467067

Ahmed MH, Hassan A (2020) Dexamethasone for the treatment of coronavirus disease (COVID-19): a review. SN Compr Clin Med 2:2637–2646. https://doi.org/10.1007/s42399-020-00610-8

doi: 10.1007/s42399-020-00610-8 pubmed: 33163859 pmcid: 7599121

Banji D, Alqahtani SS, Banji OJF, Machanchery S, Shoaib A (2021) Calming the inflammatory storm in severe COVID-19 infections: role of biologics- a narrative review. Saudi Pharm J 29:213–222. https://doi.org/10.1016/j.jsps.2021.01.005

doi: 10.1016/j.jsps.2021.01.005 pubmed: 33850422 pmcid: 8030716

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez De Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC (2020) Remdesivir for the treatment of Covid-19 — final report. N Engl J Med 383:1813–1826. https://doi.org/10.1056/NEJMoa2007764

doi: 10.1056/NEJMoa2007764 pubmed: 32445440

Bhatt K, Garimella R, Taugir R, Mehta I, Jamal M, Vijayan R, Offor R, Nwankwo K, Arif U, Waheed K, Kumari P, Lathiya M, Michel G, Pandya N, Halpern J, Nasir H, Sanchez-Gonzalez MA (2021) Effectiveness of mavrilimumab in viral infections including SARS-CoV-2 infection - a brief review. Infect Chemother 53:1. https://doi.org/10.3947/ic.2020.0109

doi: 10.3947/ic.2020.0109 pubmed: 34409778 pmcid: 8032909

Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão MPG, Brito-Sousa JD, Baía-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos JDO, Naveca FG, Xavier MS, Siqueira AM, Schwarzbold A, Croda J, Nogueira ML, Romero GAS, Bassat Q, Fontes CJ, Albuquerque BC, Daniel-Ribeiro C-T, Monteiro WM, Lacerda MVG, for the CloroCovid-19 Team (2020) Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open 3:e208857. https://doi.org/10.1001/jamanetworkopen.2020.8857

doi: 10.1001/jamanetworkopen.2020.8857 pubmed: 32330277

Bradbury CA, McQuilten Z (2022) Anticoagulation in COVID-19. The Lancet 399:5–7. https://doi.org/10.1016/S0140-6736(21)02503-4

doi: 10.1016/S0140-6736(21)02503-4

Burhan E, Syahruddin E, Isbaniah F, Desianti GA, Fachrucha F, Sari CYI, Ismail E, Astuti P, Maruli MF, Mubarak F, Rengganis AT, Bilqis HH, Taslim I, Sastria E, Wiyarta E (2023) Evaluation of safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study. Front Pharmacol 14:1205238. https://doi.org/10.3389/fphar.2023.1205238

doi: 10.3389/fphar.2023.1205238 pubmed: 37456740 pmcid: 10347402

Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J (2020) Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 146:137-146.e3. https://doi.org/10.1016/j.jaci.2020.05.019

doi: 10.1016/j.jaci.2020.05.019 pubmed: 32470486 pmcid: 7250105

Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H, Wang W, Jiang Y, Song Z, Shi Y, Sun J, Zhang Y, Xie Q, Xu Y, Ning G, Gao Y, Zhao R (2023) VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19. N Engl J Med 388:406–417. https://doi.org/10.1056/NEJMoa2208822

doi: 10.1056/NEJMoa2208822 pubmed: 36577095

Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A, Dagna L (2020) Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: a comprehensive review of available and emerging evidence at the peak of the pandemic. Front Pharmacol 11:598308. https://doi.org/10.3389/fphar.2020.598308

doi: 10.3389/fphar.2020.598308 pubmed: 33442386 pmcid: 7798432

Chamlagain R, Shah S, Sharma Paudel B, Dhital R, Kandel B (2021) Efficacy and safety of sarilumab in COVID-19: a systematic review. Interdiscip Perspect Infect Dis 2021:1–8. https://doi.org/10.1155/2021/8903435

doi: 10.1155/2021/8903435

Chavda VP, Patel AB, Vaghasiya DD (2022) SARS-CoV-2 variants and vulnerability at the global level. J Med Virol 94:2986–3005. https://doi.org/10.1002/jmv.27717

doi: 10.1002/jmv.27717 pubmed: 35277864 pmcid: 9088647

Chen Y, Li M-X, Lu G-D, Shen H-M, Zhou J (2021) Hydroxychloroquine/chloroquine as therapeutics for COVID-19: truth under the mystery. Int J Biol Sci 17:1538–1546. https://doi.org/10.7150/ijbs.59547

doi: 10.7150/ijbs.59547 pubmed: 33907517 pmcid: 8071775

Cremer PC, Abbate A, Hudock K, McWilliams C, Mehta J, Chang SY, Sheng CC, Van Tassell B, Bonaventura A, Vecchié A, Carey B, Wang Q, Wolski KE, Rajendram P, Duggal A, Wang TS, Paolini JF, Trapnell BC, Gladish D, Myers K, Kuramochi Y, Sewell C, Balog C, Kosty Sweeny D, Kandrac J, Spencer S, Goyanes A, Sahoo D, Dugar S, Aguillon Prada R, Nichols D, Celiberti J, Partisano A, Fang F, Coehlo J, Perrin R, Mandell B, Gordon S, Wiedemann H, Young J, Greer J, Ho A-C, Ladd A, Mihalick V, Montpetit A, O’Brine J, Owen C, Pal M, Priday A, Raj Sedhai Y, Wohlford G, Hummel N, Korbee L (2021) Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol 3:e410–e418. https://doi.org/10.1016/S2665-9913(21)00070-9

doi: 10.1016/S2665-9913(21)00070-9 pubmed: 33754144 pmcid: 7969143

Criner GJ, Lang FM, Gottlieb RL, Mathews KS, Wang TS, Rice TW, Madduri D, Bellam S, Jeanfreau R, Case AH, Glassberg MK, Lyon GM, Ahmad K, Mendelson R, DiMaio JM, Tran MP, Spak CW, Abbasi JA, Davis SG, Ghamande S, Shen S, Sherman L, Lowry S (2022) Anti-granulocyte–macrophage colony–stimulating factor monoclonal antibody gimsilumab for COVID-19 pneumonia: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 205:1290–1299. https://doi.org/10.1164/rccm.202108-1859OC

doi: 10.1164/rccm.202108-1859OC pubmed: 35290169 pmcid: 9873114

Dauner DG, Dauner KN (2021) Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic. J Am Pharm Assoc 61:293–298. https://doi.org/10.1016/j.japh.2021.01.007

doi: 10.1016/j.japh.2021.01.007

Du P, Geng J, Wang F, Chen X, Huang Z, Wang Y (2021) Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome. Int J Med Sci 18:1356–1362. https://doi.org/10.7150/ijms.53564

doi: 10.7150/ijms.53564 pubmed: 33628091 pmcid: 7893562

El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S (2020) Repurposing anticancer drugs for the management of COVID-19. Eur J Cancer 141:40–61. https://doi.org/10.1016/j.ejca.2020.09.014

doi: 10.1016/j.ejca.2020.09.014 pubmed: 33125946 pmcid: 7508523

Eltayb WA, Abdalla M, Rabie AM (2023) Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega 8:5234–5246. https://doi.org/10.1021/acsomega.2c03881

doi: 10.1021/acsomega.2c03881 pubmed: 36798145 pmcid: 9897045

Fanlo P, Gracia-Tello BDC, Fonseca Aizpuru E, Álvarez-Troncoso J, Gonzalez A, Prieto-González S, Freire M, Argibay AB, Pallarés L, Todolí JA, Pérez M, Buján-Rivas S, Ibáñez B, GEAS-SEMI Group, Arnáez R, Huarte E, Sanchez J, Zabalza E, Garcia-Rey R, Gonzalo M, Diez-Galán L, De La Rica-Escuín M, Martinez-Lostao L, Marín Ballvé A, Taboada-Martínez ML, Pampín-Sánchez R, Helguera-Amézua C, Fernández-Madera-Martínez R, García-Coya E, Álvarez-Suarez AM, Robles Á, Noblejas A, Soto C, Martínez E, Arnalich F, Arévalo C, López-Rodríguez A, Cobeta P, Hidalgo F, Diz S, González P, Bara N, Fabregate M, Jiménez J, Zhilina S, Pellicer-Ariño M, Rodríguez-Núñez O, Ribot-Grabalosa J, Costafreda-Mas M, Tomé-Pérez A, Hospital-Vidal T, Ladino-Vázquez A, Morancho-Sesé A, Salazar-Rustarazo A, Gabara-Xancó C, Gonzalez-Quintela A, Sopeña B, Alende-Sixto R, Esteban H, Rodriguez-Nuñez N, Andrade-Piña AH, Sanchidrian-Chapinal MÁ, Varela P, Taboada M, Maure-Noia B, López-Domínguez A, Filloy-Mato C, Gimena-Reyes B, Samartín-Ucha M, Vázquez-Triñanes C, Fernández-Martín J, Paradela-Carreiro A, Regueira-Arcay AM, Esteban-Marcos E, Martin-Pena L, Fernández-Navarro JA, Abdilla-Bonias N, Mestre-Torres J, Marques-Soares JR, Pardos-Gea J (2023) Efficacy and safety of anakinra plus standard of care for patients with severe COVID-19: a randomized phase 2/3 clinical trial. JAMA Netw Open 6:e237243. https://doi.org/10.1001/jamanetworkopen.2023.7243

doi: 10.1001/jamanetworkopen.2023.7243 pubmed: 37027155 pmcid: 10082404

Ganta N, Alnabwani D, Keating S, Patel V, Bommu VJL, Dawoud R, Cheriyath P (2022) Rare adverse events related to nivolumab, an immune checkpoint inhibitor: a case series. Cureus. https://doi.org/10.7759/cureus.22070

doi: 10.7759/cureus.22070 pubmed: 36225436 pmcid: 10860901

Goker Bagca B, Biray Avci C (2020) The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine Growth Factor Rev 54:51–61. https://doi.org/10.1016/j.cytogfr.2020.06.013

doi: 10.1016/j.cytogfr.2020.06.013 pubmed: 32636055 pmcid: 7305753

Heo Y-A (2022) Sotrovimab: first approval. Drugs 82:477–484. https://doi.org/10.1007/s40265-022-01690-7

doi: 10.1007/s40265-022-01690-7 pubmed: 35286623 pmcid: 8919156

Holubar M, Subramanian A, Purington N, Hedlin H, Bunning B, Walter KS, Bonilla H, Boumis A, Chen M, Clinton K, Dewhurst L, Epstein C, Jagannathan P, Kaszynski RH, Panu L, Parsonnet J, Ponder EL, Quintero O, Sefton E, Singh U, Soberanis L, Truong H, Andrews JR, Desai M, Khosla C, Maldonado Y (2022) Favipiravir for treatment of outpatients with asymptomatic or uncomplicated coronavirus disease 2019: a double-blind, randomized, placebo-controlled, phase 2 trial. Clin Infect Dis 75:1883–1892. https://doi.org/10.1093/cid/ciac312

doi: 10.1093/cid/ciac312 pubmed: 35446944 pmcid: 9047233

Hossen MdS, Barek MA, Jahan N, Safiqul Islam M (2020) A review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med 2:1777–1789. https://doi.org/10.1007/s42399-020-00485-9

doi: 10.1007/s42399-020-00485-9 pubmed: 32904710 pmcid: 7457893

Huang Y, Yang C, Xu X, Xu W, Liu S (2020) Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 41:1141–1149. https://doi.org/10.1038/s41401-020-0485-4

doi: 10.1038/s41401-020-0485-4 pubmed: 32747721 pmcid: 7396720

Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, Ng Y-Y, Lo J, Chan J, Tam AR, Shum H-P, Chan V, Wu AK-L, Sin K-M, Leung W-S, Law W-L, Lung DC, Sin S, Yeung P, Yip CC-Y, Zhang RR, Fung AY-F, Yan EY-W, Leung K-H, Ip JD, Chu AW-H, Chan W-M, Ng AC-K, Lee R, Fung K, Yeung A, Wu T-C, Chan JW-M, Yan W-W, Chan W-M, Chan JF-W, Lie AK-W, Tsang OT-Y, Cheng VC-C, Que T-L, Lau C-S, Chan K-H, To KK-W, Yuen K-Y (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet 395:1695–1704. https://doi.org/10.1016/S0140-6736(20)31042-4

doi: 10.1016/S0140-6736(20)31042-4

Joyce RP, Hu VW, Wang J (2022) The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med Chem Res 31:1637–1646. https://doi.org/10.1007/s00044-022-02951-6

doi: 10.1007/s00044-022-02951-6 pubmed: 36060104 pmcid: 9425786

Keystone E, Omair MA (2015) Chapter 62: Interleukin-6 inhibition, in: Rheumatology (6th Edition). Elsevier, Volume 1, pp 485–491. https://doi.org/10.1016/B978-0-323-09138-1.00062-0

Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M (2022) Current evidence on the use of anakinra in COVID-19. Int Immunopharmacol 111:109075. https://doi.org/10.1016/j.intimp.2022.109075

doi: 10.1016/j.intimp.2022.109075 pubmed: 35905562 pmcid: 9296834

Koseki T, Nakajima K, Iwasaki H, Yamada S, Takahashi K, Doi Y, Mizuno T (2022) Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. Int J Infect Dis 115:218–223. https://doi.org/10.1016/j.ijid.2021.12.324

doi: 10.1016/j.ijid.2021.12.324 pubmed: 34910957

Lescure F-X, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N, Hagino O, Bazzalo IJ, Casas MM, Nuñez SA, Pere Y, Ibarrola CM, Solis Aramayo MA, Cuesta MC, Duarte AE, Gutierrez Fernandez PM, Iannantuono MA, Miyazaki EA, Silvio JP, Scublinsky DG, Bales A, Catarino D, Fiss E, Mohrbacher S, Sato V, Baylao A, Cavalcante A, Correa F, De Andrade CA, Furtado J, Ribeiro Filho N, Telles V, Trevelin LT, Vipich R, Boldo R, Borges P, Lobo S, Luckemeyer G, Machado L, Alves MB, Iglessias AC, Lago MM, Santos DW, Chapdelaine H, Falcone EL, Jamal R, Luong M-L, Durand M, Doucet S, Carrier F-M, Coburn BA, Del Sorbo L, Walmsley SL, Belga S, Chen LY, Mah AD, Steiner T, Wright AJ, Hajek J, Adhikari N, Fowler RA, Daneman N, Khwaja KA, Shahin J, Gonzalez C, Silva R, Lindh M, Maluenda G, Fernandez P, Oyonarte M, Lasso M, Boyer A, Bronnimann D, Bui H-N, Cazanave C, Chaussade H, Desclaux A, Ducours M, Duvignaud A, Malvy D, Martin L, Neau D, Nguyen D, Pistone T, Soubrane-Wirth G, Leitao J, Allavena C, Biron C, Bouchez S, Gaborit B, Gregoire A, Le Turnier P, Lecompte A-S, Lecomte R, Lefebvre M, Raffi F, Boutoille D, Morineau PH, Guéry R, Chatelus E, Dumoussaud N, Felten R, Luca F, Goichot B, Schneider F, Taquet M-C, Groh M, Roumier M, Neuville M, Bachelard A, Isernia V, Lescure F-X, Phung B-C, Rachline A, Sautereau A, Vallois D, Bleher Y, Boucher D, Coudon C, Esnault J, Guimard T, Leautez-Nainville S, Merrien D, Morrier M, Motte-Vincent P, Gabeff R, Leclerc H, Cozic C, Decours R, Février R, Colin G, Abgrall S, Vignes D, Sterpu R, Kuellmar M, Meersch-Dini M, Weiss R, Zarbock A, Antony C, Berger M, Brenner T, Taube C, Herbstreit F, Dolff S, Konik M, Schmidt K, Zettler M, Witzke O, Boell B, Garcia Borrega J, Koehler P, Zander T, Dusse F, Al-Sawaf O, Köhler P, Eichenauer D, Kochanek M, Shimabukuro-Vornhagen A, Mellinghoff S, Claßen A, Heger J-M, Meyer-Schwickerath C, Liedgens P, Heindel K, Belkin A, Biber A, Gilboa M, Levy I, Litachevsky V, Rahav G, Finesod Wiedner A, Zilberman-Daniels T, Oster Y, Strahilevitz J, Sviri S, Baldissera EM, Campochiaro C, Cavalli G, Dagna L, De Luca G, Della Torre E, Tomelleri A, Bernasconi De Luca D, Capetti AF, Coen M, Cossu MV, Galli M, Giacomelli A, Gubertini GA, Rusconi S, Burastero GJ, Digaetano M, Guaraldi G, Meschiari M, Mussini C, Puzzolante C, Volpi S, Aiello M, Ariani A, Chetta AA, Frizzelli A, Ticinesi A, Tuttolomondo D, Aliberti S, Blasi FB, Di Pasquale MF, Misuraca S, Pilocane T, Simonetta E, Aghelmo AM, Angelini C, Brunetta E, Canonica GW, Ciccarelli M, Dal Farra S, De Santis M, Ferri S, Folci M, Guidelli GM, Heffler EM, Loiacono F, Malipiero G, Paoletti G, Pedale R, Puggioni FA, Racca F, Zumbo A, Satou M, Honda H, Lisun T, Protsenko D, Rubtsov N, Beloglazova I, Fomina D, Lysenko M, Serdotetskova S, Firstov V, Gordeev I, Kokorin I, Komissarova K, Lapochkina N, Luchinkina E, Malimon V, Mamedguseyinova S, Polubatonova K, Suvorova N, Arribas J, Borobia Perez AM, De La Calle Prieto F, Figueira JC, Motejano Sanchez R, Mora-Rillo M, Prados Sanchez C, Queiruga Parada J, Fernandez Arnalich F, Guerro Barrientos M, Bendala Estrada A, Caballero Marcos A, Garcia Leoni ME, García-Martínez R, Collado AM, Munoz Garcia P, TorresDoRego A, VillalbaGarcía MV, Burrillo A, ValerioMinero M, GijonVidaurreta P, InfanteHerrero S, Velilla E, Machado M, Olmedo M, Pinilla B, AlmiranteGragera B, CañasRuano MDLE, ContrerasMedina S, CortésHerrera A, FalcóFerrer V, FerrerRoca R, NuvialsCasals X, RiberaPascuet E, SuanzesDiez P, RebolloCastro P, GarciaAlcaide F, Soriano A, OliverCaldes A, GonzálezCordón A, Cardozo C, De La MoraCañizo L, PenaLópez R, Chamorro S, Crespillo-Andujar C, EscuderoSanchez R, Fortún-Abete J, Monge-Maillo B, MorenoZamora A, Norman F, SanchezConde M, SerranoVillar S, Vizcarra P (2021) Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(522):532. https://doi.org/10.1016/S2213-2600(21)00099-0

doi: 10.1016/S2213-2600(21)00099-0

Lim EHT, Vlaar APJ, Brouwer MC, Van De Beek D (2023) Inhibiting C5 in patients with severe COVID-19—the incorrect target? Lancet Respir Med 11:e80. https://doi.org/10.1016/S2213-2600(23)00189-3

doi: 10.1016/S2213-2600(23)00189-3 pubmed: 37307842

Lin HXJ, Cho S, Meyyur Aravamudan V, Sanda HY, Palraj R, Molton JS, Venkatachalam I (2021) Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection 49:401–410. https://doi.org/10.1007/s15010-020-01557-7

doi: 10.1007/s15010-020-01557-7 pubmed: 33389708 pmcid: 7778417

Magro P, Zanella I, Pescarolo M, Castelli F, Quiros-Roldan E (2021) Lopinavir/ritonavir: repurposing an old drug for HIV infection in COVID-19 treatment. Biomed J 44:43–53. https://doi.org/10.1016/j.bj.2020.11.005

doi: 10.1016/j.bj.2020.11.005 pubmed: 33608241

Mali KR, Eerike M, Raj GM, Bisoi D, Priyadarshini R, Ravi G, Chaliserry LF, Janti SS (2023) Efficacy and safety of molnupiravir in COVID-19 patients: a systematic review. Ir J Med Sci 1971–192:1665–1678. https://doi.org/10.1007/s11845-022-03139-y

doi: 10.1007/s11845-022-03139-y

Manabe T, Kambayashi D, Akatsu H, Kudo K (2021) Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 21:489. https://doi.org/10.1186/s12879-021-06164-x

doi: 10.1186/s12879-021-06164-x pubmed: 34044777 pmcid: 8159019

Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E (2022) Paxlovid: mechanism of action, synthesis, and in silico study. BioMed Res Int 2022:1–16. https://doi.org/10.1155/2022/7341493

doi: 10.1155/2022/7341493

Mazaherpour H, Sofian M, Farahani E, Abdi A, Mazaherpour S, Bavand A, Ramezani A (2022) Comparing outcomes of two antiviral therapy combinations among COVID-19 Patients. Biomed Res Int 2022:1522426. https://doi.org/10.1155/2022/1522426

Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, Fortin GM, Rayalam S, Taval S (2021) Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol 4:93. https://doi.org/10.1038/s42003-020-01577-x

doi: 10.1038/s42003-020-01577-x pubmed: 33473151 pmcid: 7817688

Mohan A, Tiwari P, Suri TM, Mittal S, Patel A, Jain A, Velpandian T, Das US, Boppana TK, Pandey RM, Shelke SS, Singh AR, Bhatnagar S, Masih S, Mahajan S, Dwivedi T, Sahoo B, Pandit A, Bhopale S, Vig S, Gupta R, Madan K, Hadda V, Gupta N, Garg R, Meena VP, Guleria R (2021) Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. J Infect Chemother 27(12):1743–1749. https://doi.org/10.1016/j.jiac.2021.08.021

doi: 10.1016/j.jiac.2021.08.021 pubmed: 34483029 pmcid: 8384587

Mouffak S, Shubbar Q, Saleh E, El-Awady R (2021) Recent advances in management of COVID-19: a review. Biomed Pharmacother 143:112107. https://doi.org/10.1016/j.biopha.2021.112107

doi: 10.1016/j.biopha.2021.112107 pubmed: 34488083 pmcid: 8390390

Nguyen T, Dima L, Willett KC (2023) Anakinra—an interleukin-1 receptor antagonist for COVID-19. Am J Ther 30:e108–e116. https://doi.org/10.1097/MJT.0000000000001603

doi: 10.1097/MJT.0000000000001603 pubmed: 36811898

Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, Dehghan N, Navaei M, Ranjbar M (2020) Effect of Arbidol (umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis 20:954. https://doi.org/10.1186/s12879-020-05698-w

doi: 10.1186/s12879-020-05698-w pubmed: 33317461 pmcid: 7734453

Noreen S, Maqbool I, Madni A (2021) Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol 894:173854. https://doi.org/10.1016/j.ejphar.2021.173854

doi: 10.1016/j.ejphar.2021.173854 pubmed: 33428898 pmcid: 7836247

Nortey RA, Kretchy IA, Koduah A, Buabeng KO (2023) Biopsychosocial analysis of antibiotic use for the prevention or management of COVID-19 infections: a scoping review. Res Soc Adm Pharm 19:573–581. https://doi.org/10.1016/j.sapharm.2022.11.011

doi: 10.1016/j.sapharm.2022.11.011

Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S (2008) Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors. J Theor Biol 254:861–867. https://doi.org/10.1016/j.jtbi.2008.07.030

doi: 10.1016/j.jtbi.2008.07.030 pubmed: 18706430 pmcid: 7094092

Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee I-H, Hu H, Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R, Phulpin C, Edgar H, Gallant J, Diaz-Cuervo H, Smith LE, Osinusi AO, Brainard DM, Bernardino JI, GS-US-540–5773 and GS-US-540–5807 Investigators (2021) Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis 73:e4166–e4174. https://doi.org/10.1093/cid/ciaa1041

doi: 10.1093/cid/ciaa1041 pubmed: 32706859

Pandey S, Pathak SK, Pandey A, Salunke AA, Chawla J, Sharma A, Sharma S, Thivari P, Ratna HVK (2020) Ivermectin in COVID-19: what do we know? Diabetes Metab. Syndr Clin Res Rev 14:1921–1922. https://doi.org/10.1016/j.dsx.2020.09.027

doi: 10.1016/j.dsx.2020.09.027

Parasher A (2021) COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 97:312–320. https://doi.org/10.1136/postgradmedj-2020-138577

doi: 10.1136/postgradmedj-2020-138577 pubmed: 32978337

Patnaik MM, Sallman DA, Mangaonkar AA, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E (2020) Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood 136:909–913. https://doi.org/10.1182/blood.2019004352

doi: 10.1182/blood.2019004352 pubmed: 32294158 pmcid: 7531999

Pourkarim F, Pourtaghi-Anvarian S, Rezaee H (2022) Molnupiravir: a new candidate for COVID-19 treatment. Pharmacol Res Perspect 10:e00909. https://doi.org/10.1002/prp2.909

doi: 10.1002/prp2.909 pubmed: 34968008

Prins MLM, Van Der Plas JL, Vissers MFJM, Berends CL, Tresch G, Soergel M, Fernández E, Van Den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC (2023) Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: a phase 2a, open-label, single-dose escalation study. Br J Clin Pharmacol 89:1105–1114. https://doi.org/10.1111/bcp.15560

doi: 10.1111/bcp.15560 pubmed: 36214216

Punekar M, Kshirsagar M, Tellapragada C, Patil K (2022) Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system. Microb Pathog 168:105608. https://doi.org/10.1016/j.micpath.2022.105608

doi: 10.1016/j.micpath.2022.105608 pubmed: 35654381 pmcid: 9160731

Rafaniello C, Ferrajolo C, Sullo MG, Gaio M, Zinzi A, Scavone C, Gargano F, Coscioni E, Rossi F, Capuano A (2021) Cardiac events potentially associated to remdesivir: an analysis from the European Spontaneous Adverse Event Reporting System. Pharmaceuticals 14:611. https://doi.org/10.3390/ph14070611

doi: 10.3390/ph14070611 pubmed: 34202350 pmcid: 8308754

Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, Forrest JI, Harari O, Quirino Dos Santos CV, Guimarães De Almeida APF, Figueiredo Neto ADD, Savassi LCM, Milagres AC, Teixeira MM, Simplicio MIC, Ribeiro LB, Oliveira R, Mills EJ, TOGETHER Investigators (2021) Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open 4:e216468. https://doi.org/10.1001/jamanetworkopen.2021.6468

doi: 10.1001/jamanetworkopen.2021.6468 pubmed: 33885775 pmcid: 8063069

Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, Cavalcante AW, Overcash JS, Hanania NA, Skarbnik A, Garcia-Diaz J, Gordeev I, Carratalà J, Gordon O, Graham E, Lewin-Koh N, Tsai L, Tuckwell K, Cao H, Brainard D, Olsson JK (2021) Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med 47:1258–1270. https://doi.org/10.1007/s00134-021-06507-x

doi: 10.1007/s00134-021-06507-x pubmed: 34609549 pmcid: 8490137

Satarker S, Ahuja T, BanerjeeEDograAgarwalNampoothiri MVBSTM (2020) Hydroxychloroquine in COVID-19: potential mechanism of action against SARS-CoV-2. Curr Pharmacol Rep 6:203–211. https://doi.org/10.1007/s40495-020-00231-8

doi: 10.1007/s40495-020-00231-8 pubmed: 32864299 pmcid: 7443392

Schwartz RA, Suskind RM (2020) Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Dermatol Ther 33(4):e13785. https://doi.org/10.1111/dth.13785

Shah PL, Orton CM, Grinsztejn B, Donaldson GC, Crabtree Ramírez B, Tonkin J, Santos BR, Cardoso SW, Ritchie AI, Conway F, Riberio MPD, Wiseman DJ, Tana A, Vijayakumar B, Caneja C, Leaper C, Mann B, Samson A, Bhavsar PK, Boffito M, Johnson MR, Pozniak A, Pelly M, Foster D, Shabbir N, Connolly S, Cartier A, Jaffer S, Winpenny C, Daby D, Pepper S, Adamson C, Carungcong J, Nundlall K, Fedele S, Samson-Fessale P, Schoolmeesters A, De Almeida G, Martins L, Bull R, Correia Da Costa P, Bautista C, Eleanor Flores M, Maheswaran S, Macabodbod L, Houseman R, Svensson M-L, Sayan A, Fung C, Garner J, Lai D, Nelson M, Moore L, Gidwani S, Davies G, Ouma B, Salinos C, Salha J, Yassein R, Abbasi A, Oblak M, Steward A, Thankachen M, Barker A, Fernandes C, Beatriz V, Flores L, Soler-Carracedo A, Rocca A, Maheswaran S, Martella C, Lloyd C, Nolan C, Horsford L, Martins L, Thomas L, Winstanley M, Bourke M, Branch N, Orhan O, Morton R, Saunder S, Patil S, Hughes S, Zhe W, De Leon A, Farah A, Rya G, Alizadeh K, Leong K, Trepte L, Goel N, McGown P, Kirwan U, Vilela Baião T, Marins L, Nazer S, Malaguthi De Souza R, Feitosa M, Lessa F, Silva De Magalhães E, Costenaro J, De CassiaAlvesLira R, Carolina A, CauduroDe Castro A, MachadoDaSilva A, Kliemann D, De CassiaAlvesLira R, Walker G, Norton D, Lowthorpe V, Ivan M, Lillie P, Easom N, Sierra Madero J, LópezIñiguez Á, PatriciaMuñuzuri Nájera G, PaolaAlarcónMurra C, Alanis Vega A, MuñozTrejo T, PérezRodríguez O (2023) Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. Lancet Respir Med 11:415–424. https://doi.org/10.1016/S2213-2600(22)00412-X

doi: 10.1016/S2213-2600(22)00412-X pubmed: 36528039

Shapiro AE, Sarkis E, Acloque J, Free A, Gonzalez-Rojas Y, Hussain R, Juarez E, Moya J, Parikh N, Inman D, Cebrik D, Nader A, Noormohamed N, Wang Q, Skingsley A, Austin D, Peppercorn A, Agostini ML, Parra S, Chow S, Mogalian E, Pang PS, Hong DK, Sager JE, Yeh WW, Alexander EL, Gaffney LA, Kohli A (2023) Intramuscular vs intravenous SARS-CoV-2 neutralizing antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomized noninferiority clinical trial. Open Forum Infect Dis 10:ofad354. https://doi.org/10.1093/ofid/ofad354

doi: 10.1093/ofid/ofad354 pubmed: 37577112 pmcid: 10414803

Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R (2022) Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults. Antimicrob Agents Chemother 66:e00632-e722. https://doi.org/10.1128/aac.00632-22

doi: 10.1128/aac.00632-22 pubmed: 36094202 pmcid: 9578392

Shuter J (2008) Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 4:1023–1033. https://doi.org/10.2147/TCRM.S3285

doi: 10.2147/TCRM.S3285 pubmed: 19209283 pmcid: 2621403

Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK (2020) Drug repurposing approach to fight COVID-19. Pharmacol Rep 72:1479–1508. https://doi.org/10.1007/s43440-020-00155-6

doi: 10.1007/s43440-020-00155-6 pubmed: 32889701 pmcid: 7474498

Sinha N, Balayla G (2020) Hydroxychloroquine and COVID-19. Postgrad Med J 96:550–555. https://doi.org/10.1136/postgradmedj-2020-137785

doi: 10.1136/postgradmedj-2020-137785 pubmed: 32295814

Syed YY (2021) Ravulizumab: a review in atypical haemolytic uraemic syndrome. Drugs 81:587–594. https://doi.org/10.1007/s40265-021-01481-6

doi: 10.1007/s40265-021-01481-6 pubmed: 33738756 pmcid: 8052220

Temesgen Z, Burger CD, Baker J, Polk C, Libertin C, Kelley C, Marconi VC, Orenstein R, Durrant C, Chappell D, Ahmed O, Chappell G, Badley AD (2021) Lenzilumab efficacy and safety in newly hospitalized COVID-19 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial. medRxiv. https://doi.org/10.1101/2021.05.01.21256470

Tharaux P-L, Pialoux G, Pavot A, Mariette X, Hermine O, Resche-Rigon M, Porcher R, Ravaud P, Bureau S, Dougados M, Tibi A, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Yazdanpanah Y, Baron G, Perrodeau E, Vanhoye D, Kedzia C, Demerville L, Gysembergh-Houal A, Bourgoin A, Dalibey S, Raked N, Mameri L, Alary S, Hamiria S, Bariz T, Semri H, Hai DM, Benafla M, Belloul M, Vauboin P, Flamand S, Pacheco C, Walter-Petrich A, Stan E, Benarab S, Nyanou C, Montlahuc C, Biard L, Charreteur R, Dupré C, Cardet K, Lehmann B, Baghli K, Madelaine C, D’Ortenzio E, Puéchal O, Semaille C, Savale L, Harrois A, Figueiredo S, Duranteau J, Anguel N, Monnet X, Richard C, Teboul J-L, Durand P, Tissieres P, Jevnikar M, Montani D, Bulifon S, Jaïs X, Sitbon O, Pavy S, Noel N, Lambotte O, Escaut L, Jauréguiberry S, Baudry E, Verny C, Noaillon M, Lefèvre E, Zaidan M, Le Tiec CLT, Verstuyft CV, Roques A-M, Grimaldi L, Molinari D, Leprun G, Fourreau A, Cylly L, Virlouvet M, Meftali R, Fabre S, Licois M, Mamoune A, Boudali Y, Georgin-Lavialle S, Senet P, Soria A, Parrot A, François H, Rozensztajn N, Blin E, Choinier P, Camuset J, Rech J-S, Canellas A, Rolland-Debord C, Lemarié N, Belaube N, Nadal M, Siguier M, Petit-Hoang C, Chas J, Drouet E, Lemoine M, Phibel A, Aunay L, Bertrand E, Ravato S, Vayssettes M, Adda A, Wilpotte C, Thibaut P, Fillon J, Debrix I, Fellahi S, Bastard J-P, Lefèvre G, Fallet V, Gottenberg J-E, Hansmann Y, Andres E, Bayer S, Becker G, Blanc F, Brin S, Castelain V, Chatelus E, Chatron E, Collange O, Danion F, De Blay F, Demonsant E, Diemunsch P, Diemunsch S, Felten R, Goichot B, Greigert V, Guffroy A, Heger B, Hutt A, Kaeuffer C, Kassegne L, Korganow AS, Le Borgne P, Lefebvre N, Martin T, Mertes PM, Metzger C, Meyer N, Nisand G, Noll E, Oberlin M, Ohlmann-Caillard S, Poindron V, Pottecher J, Ruch Y, Sublon C, Tayebi H, Weill F, Mekinian A, Chopin D, Fain O, Garnier M, Krause Le Garrec J, Morgand M, Pacanowski J, Urbina T, McAvoy C, Pereira M, Aratus G, Berard L, Simon T, Daguenel-Nguyen A, Antignac M, Leplay C, Arlet J-B, Diehl J-L, Bellenfant F, Blanchard A, Buffet A, Cholley B, Fayol A, Flamarion E, Godier A, Gorget T, Hamada S-R, Hauw-Berlemont C, Hulot J-S, Lebeaux D, Livrozet M, Michon A, Neuschwander A, Penet M-A, Planquette B, Ranque B, Sanchez O, Volle G, Briois S, Cornic M, Elisee V, Jesuthasan D, Djadi-Prat J, Jouany P, Junquera R, Henriques M, Kebir A, Lehir I, Meunier J, Patin F, Paquet V, Tréhan A, Vigna V, Sabatier B, Bergerot D, Jouve C, Knosp C, Lenoir O, Mahtal N, Resmini L, Lescure F-X, Ghosn J, Bachelard A, Bironne T, Borie R, Bounhiol A, Boussard C, Chauffier J, Chalal S, Chalal L, Chansombat M, Crespin P, Crestani B, Daconceicao O, Deconinck L, Dieude P, Dossier A, Dubert M, Ducrocq G, Fuentes A, Gervais A, Gilbert M, Isernia V, Ismael S, Joly V, Julia Z, Lariven S, Le Gac S, Le Pluart D, Louni F, Ndiaye A, Papo T, Parisey M, Phung B, Pourbaix A, Rachline A, Rioux C, Sautereau A, Steg G, Tarhini H, Valayer S, Vallois D, Vermes P, Volpe T, Nguyen Y, Honsel V, Weiss E, Codorniu A, Zarrouk V, De Lastours V, Uzzan M, Olivier O, Rossi G, Gamany N, Rahli R, Louis Z, Boutboul D, Galicier L, Amara Y, Archer G, Benattia A, Bergeron A, Bondeelle L, De Castro N, Clément M, Darmont M, Denis B, Dupin C, Feredj E, Feyeux D, Joseph A, Lengliné E, Le Guen P, Liégeon G, Lorillon G, Mabrouki A, Mariotte E, Martin De Frémont G, Mirouse A, Molina J-M, Peffault De Latour R, Oksenhendler E, Saussereau J, Tazi A, Tudesq J-J, Zafrani L, Brindele I, Bugnet E, Celli Lebras K, Chabert J, Djaghout L, Fauvaux C, Jegu AL, Kozaliewicz E, Meunier M, Tremorin M-T, Davoine C, Madeleine I, Caillat-Zucman S, Delaugerre C, Morin F, Sene D, Burlacu R, Chousterman B, Megarbane B, Richette P, Riveline J-P, Frazier A, Vicaut E, Berton L, Hadjam T, Vasquez-Ibarra MA, Jourdaine C, Jacob A, Smati J, Renaud S, Manivet P, Pernin C, Suarez L, Semerano L, Abad S, Benainous R, Bloch Queyrat C, Bonnet N, Brahmi S, Cailhol J, Cohen Y, Comparon C, Cordel H, Dhote R, Dournon N, Duchemann B, Ebstein N, Giroux-Leprieur B, Goupil De Bouille J, Jacolot A, Nunes H, Oziel J, Rathouin V, Rigal M, Roulot D, Tantet C, Uzunhan Y, Costedoat-Chalumeau N, Ait Hamou Z, Benghanem S, Blanche P, Canoui E, Carlier N, Chaigne B, Contejean A, Dunogue B, Dupland P, Durel-Maurisse A, Gauzit R, Jaubert P, Joumaa H, Jozwiak M, Kerneis S, Lachatre M, Lafoeste H, Legendre P, Luong Nguyen LB, Marey J, Morbieu C, Mouthon L, Nguyen L, Palmieri L-J, Regent A, Szwebel T-A, Terrier B, Guerin C, Zerbit J, Cheref K, Chitour K, Cisse MS, Clarke A, Clavere G, Dusanter I, Gaudefroy C, Jallouli M, Kolta S, Le Bourlout C, Marin N, Menage N, Moores A, Peigney I, Pierron C, Saleh-Mghir S, Vallet M, Michel M, Melica G, Lelievre J-D, Fois E, Lim P, Matignon M, Guillaud C, Thiemele A, Schmitz D, Bouhris M, Belazouz S, Languille L, Mekontso-Dessaps A, Sadaoui T, Mayaux J, Cacoub P, Corvol J-C, Louapre C, Sambin S, Mariani L-L, Karachi C, Tubach F, Estellat C, Gimeno L, Martin K, Bah A, Keo V, Ouamri S, Messaoudi Y, Yelles N, Faye P, Cavelot S, Larcheveque C, Annonay L, Benhida J, Zahrate-Ghoul A, Hammal S, Belilita R, Lecronier M, Beurton A, Haudebourg L, Deleris R, Le Marec J, Virolle S, Nemlaghi S, Bureau C, Mora P, De Sarcus M, Clovet O, Duceau B, Grisot PH, Pari MH, Arzoine J, Clarac U, Faure M, Delemazure J, Decavele M, Morawiec E, Demoule A, Dres M, Vautier M, Allenbach Y, Benveniste O, Leroux G, Rigolet A, Guillaume-Jugnot P, Domont F, Desbois AC, Comarmond C, Champtiaux N, Toquet S, Ghembaza A, Vieira M, Maalouf G, Boleto G, Ferfar Y, Charbonnier F, Aguilar C, Alby-Laurent F, Alyanakian M-A, Bakouboula P, Broissand C, Burger C, Campos-Vega C, Chavarot N, Choupeaux L, Fournier B, Granville S, Issorat E, Rouzaud C, Vimpere D, Geri G, Derridj N, Sguiouar N, Meddah H, Djadel M, Chambrin-Lauvray H, Duclos-Vallée J-C, Saliba F, Sacleux S-C, Koumis I, Michot J-M, Stoclin A, Colomba E, Pommeret F, Willekens C, Sakkal M, Da Silva R, Dejean V, Mekid Y, Ben-Mabrouk I, Pradon C, Drouard L, Camara-Clayette V, Morel A, Garcia G, Mohebbi A, Berbour F, Dehais M, Pouliquen A-L, Klasen A, Soyez-Herkert L, London J, Keroumi Y, Guillot E, Grailles G, El Amine Y, Defrancq F, Fodil H, Bouras C, Dautel D, Gambier N, Dieye T, Razurel A, Bienvenu B, Lancon V, Lecomte L, Beziriganyan K, Asselate B, Allanic L, Kiouris E, Legros M-H, Lemagner C, Martel P, Provitolo V, Ackermann F, Le Marchand M, ClanHewWai A, Fremont D, Coupez E, Adda M, Duée F, Bernard L, Gros A, Henry E, Courtin C, Pattyn A, Guinot P-G, Bardou M, Maurer A, Jambon J, Cransac A, Pernot C, Mourvillier B, Servettaz A, Deslée G, Wynckel A, Benoit P, Marquis E, Roux D, Gernez C, Yelnik C, Poissy J, Nizard M, Denies F, Gros H, Mourad J-J, Sacco E, Renet S (2021) Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 9:295–304. https://doi.org/10.1016/S2213-2600(20)30556-7

doi: 10.1016/S2213-2600(20)30556-7

Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS (2023) Therapeutics for COVID-19. Nat Microbiol 8:771–786. https://doi.org/10.1038/s41564-023-01356-4

doi: 10.1038/s41564-023-01356-4 pubmed: 37142688

Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, Maruyama Y, Taoda Y, Kasamatsu K, Suto T, Kouki K, Nakahashi A, Kawashima S, Sanaki T, Toba S, Uemura K, Mizutare T, Ando S, Sasaki M, Orba Y, Sawa H, Sato A, Sato T, Kato T, Tachibana Y (2022) Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem 65:6499–6512. https://doi.org/10.1021/acs.jmedchem.2c00117

doi: 10.1021/acs.jmedchem.2c00117 pubmed: 35352927 pmcid: 8982737

Van Laar SA, De Boer MGJ, Gombert-Handoko KB, Guchelaar H, Zwaveling J (2021) Liver and kidney function in patients with Covid-19 treated with remdesivir. Br J Clin Pharmacol 87:4450–4454. https://doi.org/10.1111/bcp.14831

doi: 10.1111/bcp.14831 pubmed: 33763917

Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, Machado FR, Lopes RD, Berwanger O, Azevedo LCP, Avezum Á, Lisboa TC, Rojas SSO, Coelho JC, Leite RT, Carvalho JC, Andrade LEC, Sandes AF, Pintão MCT, Castro CG, Santos SV, De Almeida TML, Costa AN, Gebara OCE, De Freitas FGR, Pacheco ES, Machado DJB, Martin J, Conceição FG, Siqueira SRR, Damiani LP, Ishihara LM, Schneider D, De Souza D, Cavalcanti AB, Scheinberg P (2021) Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.BMJ 372:n84. https://doi.org/10.1136/bmj.n84

Villaescusa L, Zaragozá F, Gayo-Abeleira I, Zaragozá C (2022) A new approach to the management of COVID-19. Antagonists of IL-6: siltuximab. Adv Ther 39:1126–1148. https://doi.org/10.1007/s12325-022-02042-3

doi: 10.1007/s12325-022-02042-3 pubmed: 35072887 pmcid: 8784859

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https://doi.org/10.1186/1743-422X-2-69

doi: 10.1186/1743-422X-2-69 pubmed: 16115318 pmcid: 1232869

Walser M, Rothenberger S, Hurdiss DL, Schlegel A, Calabro V, Fontaine S, Villemagne D, Paladino M, Hospodarsch T, Neculcea A, Cornelius A, Schildknecht P, Matzner M, Hänggi M, Franchini M, Kaufmann Y, Schaible D, Schlegel I, Iss C, Looser T, Mangold S, Herzog C, Schiegg D, Reichen C, Radom F, Bosshart A, Lehmann A, Haeuptle MA, Zürcher A, Vagt T, Sigrist G, Straumann M, Proba K, Veitonmäki N, Dawson KM, Zitt C, Mayor J, Ryter S, Lyoo H, Wang C, Li W, Drulyte I, Du W, Binz HK, De Waal L, Stittelaar KJ, Taplin S, Lewis S, Steiner D, Van Kuppeveld FJM, Engler O, Bosch B-J, Stumpp MT, Amstutz P (2020) Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates (preprint). Immunology. https://doi.org/10.1101/2020.08.25.256339

doi: 10.1101/2020.08.25.256339

Wang F, Xiao W, Tang Y, Cao M, Shu D, Asakawa T, Xu Y, Jiang X, Zhang L, Wang W, Tang J, Huang Y, Yang Y, Yang Y, Tang R, Shen J, Lu H (2023) Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial. Lancet Reg Health - West Pac 38:100835. https://doi.org/10.1016/j.lanwpc.2023.100835

doi: 10.1016/j.lanwpc.2023.100835 pubmed: 37484496 pmcid: 10362366

Wu R, Wang L, Kuo H-CD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ, Amorosa L, Brunetti L, Kong A-N (2020) An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep 6:56–70. https://doi.org/10.1007/s40495-020-00216-7

doi: 10.1007/s40495-020-00216-7 pubmed: 32395418 pmcid: 7211915

Zhan X, Dowell S, Shen Y, Lee DL (2020) Chloroquine to fight COVID-19: a consideration of mechanisms and adverse effects? Heliyon 6:e04900. https://doi.org/10.1016/j.heliyon.2020.e04900

doi: 10.1016/j.heliyon.2020.e04900 pubmed: 32935064 pmcid: 7480339

Zhang S, Li L, Shen A, Chen Y, Qi Z (2020) Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig 40:511–518. https://doi.org/10.1007/s40261-020-00917-3

doi: 10.1007/s40261-020-00917-3 pubmed: 32337664 pmcid: 7183818

Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, Chen G, Wang K, Yu J, Wu Z, Chen X, Wang G (2021) Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother 133:110825. https://doi.org/10.1016/j.biopha.2020.110825

doi: 10.1016/j.biopha.2020.110825 pubmed: 33378989

Adverse drug reactions associated with COVID-19 management.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Vivek Chavda (V)

Payal Dodiya (P)

Vasso Apostolopoulos (V)

Classifications MeSH